BioSpace News Archive

STRATA Skin Sciences, Inc. announced an initiative aimed at expanding insurance coverage for essential treatments for conditions such as mycosis fungoides, lichen planus, alopecia areata, and cutaneous T-Cell lymphoma, with an initial targeted focus on expanding coverage for vitiligo and atopic dermatitis, skin diseases effecting up to 3 and 16 million people in the United States respectively.

Verismo Therapeutics, a clinical-stage CAR-T company developing the novel KIR-CAR platform technology, today announced that it has activated a second clinical site for its STAR-101 Phase 1 clinical trial at The University of Texas MD Anderson Cancer Center.

Immunome, Inc. today announced that Clay Siegall, Ph.D., President and CEO of Immunome, will present at the Leerink Partners 2024 Global Biopharma Conference on Tuesday, March 12, 2024 at 4:20 p.m. ET.

Neuroelectrics announced today study results published to the preprint server medRxiv that suggest tele-supervised at-home transcranial direct current stimulation (tDCS) using Starstim over the left dorsolateral prefrontal cortex (L-DLPFC) may improve the clinical symptoms of major depressive disorder (MDD).

IceCure Medical Ltd. today announced that the Company’s Chief Executive Officer, Eyal Shamir , will present at the 34th Annual Oppenheimer Healthcare MedTech & Services Conference on Tuesday, March 12, 2024, at 8:00am EST.

Alligator Bioscience AB and Aptevo Therapeutics today announced positive interim data from the dose escalation phase of their Phase 1 trial evaluating ALG.APV-527 for the treatment of solid tumors likely to express the tumor antigen 5T4.

SurGenTec proudly announces the first implantations and 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its revolutionary OsteoFlo HydroPutty Synthetic Bone Graft.

Cyclacel Pharmaceuticals, Inc. today announced that preclinical proof-of-concept data with the Company’s fadraciclib will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, California.

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, March 28, 2024, at 4:30 p.m. Eastern Time to review 2023 fourth quarter and full year results.

RDS, the medical device start-up, today announces the granting of the CE mark for MultiSense®, its patented, wearable solution for continuous Remote Patient Monitoring.